Form 4: Inhibrx Biosciences Director Kimberly Manhard Granted 15,000 Stock Options

Inhibrx Biosciences, Inc. Director Kimberly Manhard was granted 15,000 stock options with an exercise price of $12.91, which will become fully exercisable on May 28, 2026.

Summary

• Kimberly Manhard, a Director of Inhibrx Biosciences, Inc. (INBX), acquired 15,000 stock options.
• The transaction date for the option grant was May 28, 2025.
• Each stock option has an exercise price of $12.91.
• The options will become fully exercisable on May 28, 2026, contingent upon Ms. Manhard's continued service through that date.
• The expiration date for these stock options is May 28, 2035.
• Following this transaction, Kimberly Manhard beneficially owns 15,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of options aligns director interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational news.

Positives

• The grant of stock options to a director, Kimberly Manhard, aligns her interests with those of the shareholders, incentivizing long-term company performance.
• The options have a long expiration date (May 28, 2035), providing a significant window for potential value realization.

Negatives

• The exercise of these options in the future could lead to a minor dilutive effect on existing shares, although this is standard for equity compensation.

Risks

• The value of the stock options is dependent on the future stock price of Inhibrx Biosciences, Inc. exceeding the exercise price of $12.91; if the stock price remains below this level, the options may not be exercised.
• The exercisability of the options is subject to Kimberly Manhard's continued service to the company through May 28, 2026.

Future Outlook

The grant of stock options indicates a forward-looking compensation strategy, tying a director's potential future compensation to the company's stock performance over the next decade, with exercisability commencing in May 2026.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including for companies like Inhibrx Biosciences, Inc., as a form of long-term incentive compensation designed to align the interests of leadership with shareholder value creation.

Related Party Transactions

• The grant of stock options to Kimberly Manhard, a director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon exercise of options, but also benefit from aligned director incentives.
• Kimberly Manhard (Director): Receives long-term equity compensation tied to company performance.

Next Steps

• Kimberly Manhard's continued service to Inhibrx Biosciences, Inc. until May 28, 2026, for the options to become fully exercisable.
• Potential exercise of the stock options by Kimberly Manhard at any point between May 28, 2026, and May 28, 2035, assuming the stock price is above the exercise price.

Key Dates

Keywords

Inhibrx Biosciences, INBX, Stock Options, Form 4, SEC Filing, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership